ArticleJournal of ovarian research2026
Triglyceride-glucose index and assisted reproductive outcomes in non-PCOS women: evidence from a propensity score-weighted cohort of 9,903 patients.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundInsulin resistance (IR) is a key metabolic disturbance that adversely affects assisted reproductive technology (ART) outcomes. In women with polycystic ovary syndrome (PCOS), IR has been well documented to impair oocyte quality, embryo development, and pregnancy outcomes. However, much less is known about whether IR similarly influences ART outcomes in non-PCOS women. To address this gap, this study used the triglyceride–glucose (TyG) index, a simple surrogate of IR, to evaluate its potential impact on ART outcomes in non-PCOS women. STUDY
designThis retrospective cohort study included 9,903 women without PCOS who underwent their first autologous in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) cycle between January 2020 and December 2023 at a large reproductive medicine center in China. Patients were stratified into TyG quartiles (Q1 ≤ 7.95, Q2 = 7.96–8.28, Q3 = 8.29–8.67, Q4 ≥ 8.68). Propensity score inverse probability weighting (PS-IPW) was applied to balance baseline covariates. Primary outcomes (live birth, clinical pregnancy, and miscarriage) were evaluated in fresh embryo transfer cycles. Secondary outcomes were embryologic and cycle characteristics (oocyte yield, fertilization, blastocyst formation, and stimulation duration) assessed across all fertilized cycles.
resultsAfter PS-IPW adjustment, embryologic outcomes—including oocyte retrieval, maturation, fertilization, and blastocyst formation—were comparable across TyG quartiles. Among 5,255 fresh embryo transfer cycles, clinical pregnancy, live birth, and miscarriage rates were broadly similar across TyG quartiles after PS-IPW adjustment. A small non-linear pattern was observed, with Q3 showing a modest increase in live birth (relative risk [RR] = 1.12; 95% confidence interval [CI], 1.01–1.23) and clinical pregnancy (RR = 1.09; 95% CI, 1.01–1.19) compared with Q1. Interaction analyses further suggested that this intermediate TyG pattern may be modified by reproductive history and stimulation strategy.
conclusionIn this large real-world cohort, the TyG index was not materially associated with impaired embryologic or pregnancy outcomes in non-PCOS women undergoing IVF/ICSI. Further studies are warranted to confirm these findings in diverse populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.